Portage Biotech rises on Merck collaboration for cancer therapy

Alpha Compute

08/11/2022 16:52

** Shares of Portage Biotech  PRTG.O  rise as much as 4.9%
to $6.70
    ** Co announces agreement with drugmaker Merck  MRK.N  to
study PRTG's lead therapy, PORT-2, in combination with Keytruda
in an early-to-mid stage study 
    ** PRTG says will test the combination therapy as a
potential treatment for a type of lung cancer
    ** Under terms, MRK will provide KEYTRUDA for PRTG's trial
and companies to establish a joint committee to evaluate the
combination cohorts in study 
    ** Including session's gain, stock down 39.4% YTD 
 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))